A5076068189- Machine Learning in Bioinformatics
- Advanced Proteomics Techniques and Applications
- Microbial Metabolic Engineering and Bioproduction
- Bioinformatics and Genomic Networks
- Cancer, Hypoxia, and Metabolism
- Phagocytosis and Immune Regulation
- Peptidase Inhibition and Analysis
- Immune Cell Function and Interaction
- RNA and protein synthesis mechanisms
- Hippo pathway signaling and YAP/TAZ
- ATP Synthase and ATPases Research
- vaccines and immunoinformatics approaches
- Adenosine and Purinergic Signaling
- Immunotherapy and Immune Responses
- Microtubule and mitosis dynamics
- T-cell and B-cell Immunology
Enzo Life Sciences (United States)
2023-2024
University of California, Los Angeles
2021-2023
University of Colorado Cancer Center
2023
University of Colorado Denver
2023
Abstract ABBV-CLS-484 (AC484) is a novel small molecule based immunotherapeutic drug that inhibits both PTPN2 and PTPN1 currently under clinical investigation for treating solid tumors. In preclinical syngeneic tumor models, AC484 has been shown to be efficacious as monotherapy, in conjunction with checkpoint inhibitors (ICBs) ICB-resistant tumors, well adoptive cellular therapy (Baumgartner et al, Nature 2023). Given the potent efficacy of this immunomodulatory compound, we sought...
Cell signaling is orchestrated in part through a network of protein kinases and phosphatases. Dysregulation kinase widespread diseases such as cancer readily targetable inhibitors. Mass spectrometry-based analysis can provide global view regulation, but mining these data complicated by its stochastic coverage the proteome, measurement substrates rather than kinases, scale data. Here, we implement dual motif clustering (DDMC) strategy that simultaneously clusters peptides into similarly...
<h3>Background</h3> Dendtritic cell (DC) vaccine therapies have so far demonstrated limited success as cancer therapeutics. Recently, cDC1 been shown to support CD8 and CD4 activation, both types were necessary for anti-tumor responses.<sup>1 2</sup> <h3>Methods</h3> To test the ability of promote these responses, we designed produced a stabilized Xcl1 protein molecule fused Fc-chicken ovalbumin (OVA) model antigen that specifically engages activate by targeting Xcr1-Xcl1 interaction....
Receptor tyrosine kinase (RTK)-targeted therapies are often effective but invariably limited by drug resistance. A major mechanism of acquired resistance involves "bypass" switching to alternative pathways driven non-targeted RTKs that restore proliferation. One such RTK is AXL whose overexpression, frequently observed in bypass resistant tumors, drives both cell survival and associated malignant phenotypes as epithelial-to-mesenchymal (EMT) transition migration. However, the signaling...
<h3>Background</h3> Metabolic alterations within the tumor microenvironment are thought to contribute immunotherapy resistance. Dysregulation of metabolism in cancer cells affects expression surface markers and secreted metabolites, thereby impeding immune surveillance, suppressing infiltration, dismantling anti-tumor cell function. Targeting metabolic vulnerabilities has therefore emerged as an avenue for therapeutic development. <h3>Methods</h3> We applied genome-scale models (GEMs),...
Abstract Cell signaling is orchestrated in part through a network of protein kinases and phosphatases. Dysregulation kinase widespread diseases such as cancer readily targetable inhibitors enzymatic activity. Mass spectrometry-based analysis can provide global view regulation but making sense these data complicated by its stochastic coverage the proteome, measurement substrates rather than itself, scale collected. Here, we implement dual motif clustering strategy (DDMC) that simultaneously...